Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $202.30, for a total transaction of $606,900.00. Following the sale, the insider owned 147,882 shares in the company, valued at approximately $29,916,528.60. This trade represents a 1.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, March 10th, Solomon Moshkevich sold 915 shares of Natera stock. The stock was sold at an average price of $204.13, for a total value of $186,778.95.
• On Monday, March 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $199.85, for a total value of $599,550.00.
• On Tuesday, February 3rd, Solomon Moshkevich sold 1,639 shares of Natera stock. The shares were sold at an average price of $230.77, for a total transaction of $378,232.03.
• On Monday, February 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $231.44, for a total transaction of $694,320.00.
• On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The stock was sold at an average price of $237.66, for a total value of $285,192.00.
• On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The stock was sold at an average price of $240.53, for a total value of $243,656.89.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The stock was sold at an average price of $235.00, for a total transaction of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The shares were sold at an average price of $234.74, for a total transaction of $5,447,141.70.

Natera Price Performance

NTRA stock opened at $207.98 on Friday. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36. The company has a market cap of $29.48 billion, a P/E ratio of -135.93 and a beta of 1.68. The stock’s fifty day moving average price is $207.26 and its 200-day moving average price is $209.16.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, topping the consensus estimate of ($0.46) by $0.81. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The company had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. During the same quarter in the previous year, the company posted ($0.41) earnings per share. As a group, analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Mozayyx Management LLC bought a new position in Natera during the fourth quarter valued at $309,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Natera in the 4th quarter worth $175,000. Reflection Asset Management bought a new stake in shares of Natera in the 4th quarter worth about $29,000. Tobam raised its position in shares of Natera by 24,935.0% during the 4th quarter. Tobam now owns 5,007 shares of the medical research company’s stock valued at $1,147,000 after buying an additional 4,987 shares in the last quarter. Finally, Groupama Asset Managment raised its position in shares of Natera by 19.5% during the 4th quarter. Groupama Asset Managment now owns 92,256 shares of the medical research company’s stock valued at $21,135,000 after buying an additional 15,072 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. BTIG Research boosted their price objective on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a research note on Friday, December 5th. Guggenheim raised their target price on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Canaccord Genuity Group reaffirmed a “buy” rating on shares of Natera in a report on Monday, January 12th. Robert W. Baird upped their price target on shares of Natera from $239.00 to $257.00 and gave the stock an “outperform” rating in a research report on Friday, February 27th. Finally, Citigroup began coverage on shares of Natera in a research note on Wednesday, January 7th. They issued a “buy” rating and a $300.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $253.47.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.